dalteparin has been researched along with Infarction, Middle Cerebral Artery in 7 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thus clinical application of enoxaparin treatment in stroke warrants serious consideration." | 1.31 | Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. ( Mary, V; Stutzmann, JM; Uzan, A; Wahl, F, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, NW | 1 |
| Chang, HW | 1 |
| Chang, WN | 1 |
| Huang, CR | 1 |
| Lin, TK | 1 |
| Chen, SD | 1 |
| Lui, CC | 1 |
| Wang, KW | 1 |
| Cheng, BC | 1 |
| Hung, PL | 1 |
| Chang, CS | 1 |
| Lu, CH | 1 |
| Lai, CC | 1 |
| Hu, CJ | 1 |
| Koduri, S | 1 |
| Wilkinson, DA | 1 |
| Griauzde, JM | 1 |
| Gemmete, JJ | 1 |
| Maher, CO | 1 |
| Mooney, T | 1 |
| Joseph, P | 1 |
| Laalou, FZ | 1 |
| Kuntzmann, H | 1 |
| Mahoudeau, G | 1 |
| Kremer, S | 1 |
| Pain, L | 1 |
| De Blanche, LE | 1 |
| Schmitz, ML | 1 |
| Johnson, CE | 1 |
| Best, TH | 1 |
| Drummond-Webb, JJ | 1 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Uzan, A | 1 |
| Stutzmann, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine[NCT04507178] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-02-02 | Recruiting | ||
| Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke[NCT00836355] | 6 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Too few acute stroke patients available to meet enrollment requirements.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Successful surgical management of a neonate with a saddle pulmonary embolus.
Topics: Anticoagulants; Arm; Cardiopulmonary Bypass; Ductus Arteriosus, Patent; Embolectomy; Enoxaparin; Fem | 2004 |
6 other studies available for dalteparin and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Prognostic factors and therapeutic outcome of isolated symptomatic middle cerebral artery stenosis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Constriction, Pathologic; Female; Humans; Infarction | 2005 |
A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke.
Topics: Aged, 80 and over; Anticoagulants; Fibrinolytic Agents; Hospitalization; Humans; Infarction, Middle | 2006 |
Development of bilateral dural arteriovenous fistulae following pial synangiosis for moyamoya syndrome: case report.
Topics: Adolescent; Anterior Cerebral Artery; Anticoagulants; Carotid Arteries; Central Nervous System Vascu | 2019 |
Purple toes syndrome following stroke thrombolysis and warfarin therapy.
Topics: Acute Kidney Injury; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism, Cholesterol; | 2014 |
[Postoperative ischemic acute stroke and thrombolytic therapy].
Topics: Acute Disease; Aged; Anticoagulants; Aphasia, Broca; Aspirin; Cholesteatoma; Ear Diseases; Ear, Exte | 2009 |
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.
Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa | 2001 |
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.
Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa | 2001 |
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.
Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa | 2001 |
Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity.
Topics: Animals; Blood Coagulation; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxapa | 2001 |